Medicine and Dentistry
Antiangiogenic Activity
100%
Prostaglandin E2
100%
Cancer Cell
100%
Lung Cancer
100%
Prostaglandin Synthase
100%
Histone Deacetylase
100%
15 Hydroxyprostaglandin Dehydrogenase
83%
Angiogenesis
66%
Trichostatin A
66%
Histone Deacetylase Inhibitor
66%
Cyclooxygenase 2
50%
Endothelial Cell
33%
Cell Proliferation
33%
Capillary
33%
Indometacin
33%
Cytokine
16%
Neoplasm
16%
Adverse Event
16%
Carcinogenesis
16%
Vorinostat
16%
Cyclooxygenase 1
16%
Celecoxib
16%
Keyphrases
Antiangiogenic Activity
100%
Cyclooxygenase Inhibitors
100%
Histone Deacetylase Inhibitor (HDACi)
100%
Lung Cancer Cells
100%
Prostaglandin E2
85%
15-hydroxyprostaglandin Dehydrogenase (15-PGDH)
71%
Angiogenesis
57%
Trichostatin A
57%
Cyclooxygenase-2
42%
Co-treatment
42%
Indomethacin
28%
Lung Cancer
28%
Capillary Formation
28%
Endothelial Cell Proliferation
28%
Adverse Effects
14%
Blockage
14%
Angiogenic
14%
Antiangiogenic
14%
Oncogenesis
14%
Conditioned Medium
14%
Cyclooxygenase-1/2
14%
Pro-proliferative
14%
Inhibitor Therapy
14%
Vorinostat
14%
Tumor Suppression
14%
Celecoxib
14%
Pharmacology, Toxicology and Pharmaceutical Science
Antiangiogenic
100%
Lung Cancer
100%
Prostaglandin E2
100%
Histone Deacetylase
100%
Prostaglandin Synthase
100%
15 Hydroxyprostaglandin Dehydrogenase
83%
Trichostatin A
66%
Histone Deacetylase Inhibitor
66%
Cyclooxygenase 2
50%
Indometacin
33%
Neoplasm
16%
Adverse Event
16%
Cytokine
16%
Carcinogenesis
16%
Vorinostat
16%
Celecoxib
16%
Cyclooxygenase 1
16%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Prostaglandin E2
100%
Cyclooxygenase
100%
Antiangiogenic Activity
100%
Histone Deacetylase
100%
Oxidoreductase
83%
Dehydrogenase
83%
Angiogenesis
66%
Trichostatin A
66%
Cell Proliferation
33%
Enzyme
16%
Cytokine
16%
Carcinogenesis
16%
Celecoxib
16%